Ackerman Capital Advisors’s AbbVie ABBV Stock Holding History

Ackerman Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,000	Closed	-$218K	–	143
2019 Q2	$218K	Buy	+3,000	New	+$236K	1.07%	32

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ackerman Capital Advisors's ABBV Position: Q3 2019 in Review

Ackerman Capital Advisors sold out of AbbVie (ABBV) in Q3 2019, closing a stake of 3,000 shares — an estimated $218K sold.

Ackerman Capital Advisors first reported a position in ABBV in Q2 2019 and held it in 1 quarter. The position peaked at $218K in Q2 2019. 2,002 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

Ackerman Capital Advisors reported no remaining AbbVie position as of Q3 2019 after selling out during the quarter.
Ackerman Capital Advisors sold 3,000 AbbVie shares in Q3 2019, an estimated $218K.
Ackerman Capital Advisors first reported a position in AbbVie in Q2 2019 and held it in 1 quarter.
Ackerman Capital Advisors's AbbVie position peaked at $218K in Q2 2019.
2,002 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on Ackerman Capital Advisors's 13F filing for Q3 2019, filed 9 Oct 2019.